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Introduction
The guidelines for an appropriate use of antibiotic therapy
recommend de-escalation as soon as the culture sensitivity
results are available.There was a great need to study the
frequency of de-escalation, no change and escalation of
antibiotics and its impact in septic patients in an Indian
ICU setting in view of rising burden of drug resistance and
health care cost.
Objectives
To determine the rate of de-escalation of the empiric
antimicrobial treatment in ICU patients admitted with
sepsis. The characteristics of antimicrobial treatment
associated with de-escalation & its impact on ICU
length of stay, hospital length of stay (LOS) and 30 day
mortality were determined.
Methods
We carried out a prospective observational study enrolling
patients admitted to the ICU with sepsis from 01/02/2014
to 01/03/2015. Both the medical and surgical units of the
ICU were included. “No change” was defined as when
empiric therapy was maintained without modification,
“Escalation of therapy” was defined when there’s a switch
to or addition of an antibiotic with a broader spectrum,
and “De-escalation” when there’s a switch to or interrup-
tion of a drug class resulting in a less broad spectrum of
coverage. If antimicrobial change consisted of escalation
and de-escalation (i.e. switch to or addition of an antibiotic
with a broader spectrum but also withdrawal of another
antibiotic), the patient was assigned to “escalation group”
for statistical analysis.
Results
The total number of patients enrolled were 315 out of
which 17 patients were excluded due to death before
culture results were available. The characteristics
observed among the therapeutic strategy groups were
seen in tables 1, 2.
The most common antibiotic after de-escalation&
antibiotic in No Change group was Betalactam + beta
lactamase inhibitor.
Apollo Health City, Critical Care Medicine, Hyderabad, India
Table 1. Patient characteristics with therapeutic strategy
Variable No change n De-escalation n Escalation n P value
Number of patients 148 74 76
Age in years 57.62 57.81 58.18 0.96
HOSPITAL length of stay in days 11.41 10.68 19.21 0.0001
APACHE II score at admission 15.3 15.84 20.11 0.0001
SOFA score at admission 6.07 6.65 8.08 0.004
Number of patients expired at 30 days after admission 20 10 26 0.0001
number of medical patients 144 64 66 0.003
Number of patients requiring vasopressors 20 16 34 0.0001
ICU length of stay in days 5.85 6.24 12.42 0.0001
Jakkinaboina and Swarna Deepak Intensive Care Medicine Experimental 2015, 3(Suppl 1):A405
http://www.icm-experimental.com/content/3/S1/A405
© 2015 Jakkinaboina et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly cited.
The statistically significant factors which increased the
30 day mortality are Escalation of antibiotics, Increased
ICU LOS, Increased APACHE II and SOFA scores at
admission, medical patients, vasopressor requirement,
lung as the source of infection, Infection with MDR
organisms.
The statistically significant factors which increased the
ICU LOS are use of vasopressors, Comorbidities,
Table 2. Patient characteristics with therapeutic strategy
Variable No change n De-escalation n Escalation n P
value
Number of initial empirical antibiotics 1 58 26 32 0.007
Number of initial empirical antibiotics 2 72 26 36
Number of initial empirical antibiotics 3 18 22 8
Most Common initial empirical antibiotic beta lactam +beta lactamase
inhibitor
Carbapenem beta lactam +beta lactamase
inhibitor
0.0001
Most Common Escalated /De-escalated
Antibiotic
beta lactam +beta lactamase
inhibitor





Multi drug resistant organisms 6 8 34 0.0001
ESBL organisms 4 4 10 0.0001
Most Common Source of infection Lung Lung Lung
H1N1 POSITIVE patients 29 10 6 0.062
Figure 1 The characteristics of the overall group of patients.
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Figure 2 Comparison between survivors and non survivors at 30 days.
Table 3 Prevalence of organisms in patient groups. The frequency of organisms in culture positive cases.
ORGANISM ISOLATED NO CHANGE n DE ESCALATION n ESCALATION n Total n (%)
Fungal infections 4 2 8 14(9.39%)
Non ESBL Gram Negative organisms 12 10 8 30(20.13%)
ESBL Gram negative organisms 4 4 10 18(12.08%)
MDR organisms 6 8 34 48(32.21%)
MRSA organisms 0 6 0 6(4.02%)
MSSA organisms 0 2 2 4(2.68%)
Vancomycin Resistant Enterococcus 2 0 0 2(1.34%)
Stenotrophomonas maltophila 4 4 4 12(8.05%)
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APACHE II at admission, SOFA at admission, MDR
organisms, escalation of antibiotic.
Conclusions
Escalation of antibiotics resulted in statistically significant
increase in the mortality and increased length of stay in
the ICU and hospital. No significant differences were
observed with respect to ICU length of stay, Hospital
length of stay and 30 day mortality among No Change &
De Escalation groups.
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